The Health Information and Quality Authority (HIQA) has affirmed that the vaccine for Respiratory Syncytial Virus (RSV) is both safe and effective. However, the authority has noted that the financial implications of widespread immunisation could be significant.
RSV is a common respiratory virus that can lead to severe illness in infants and older adults. The vaccine’s development has been a critical advancement in public health, promising to reduce the burden of this virus on vulnerable populations.
Despite its benefits, the vaccine’s high cost presents a challenge for healthcare systems. HIQA’s assessment suggests that while the immunisation could prevent hospitalisations and serious health complications, the economic feasibility of providing it to all at-risk groups requires careful consideration.
As healthcare policymakers deliberate on the potential inclusion of the RSV vaccine in national immunisation programmes, balancing cost against public health benefits will be crucial.
Leave a Reply